An anti-ICAM1 antibody–drug conjugate has displayed potent anti-myeloma cytotoxicity in vitro and in vivo (Sherbenou et al., 2020); therefore, this anti-ICAM1 antibody–drug conjugate should be further studied for toxicity and if proven safe, tested for clinical efficacy in patients with relapsed or refractory multiple myeloma. Here, ICAM1 is linked to plasma cell myeloma.